- $2.10bn
- $1.94bn
- $276.26m
Vericel Corp reports results for the quarter ended in March - Earnings Summary
Vericel Corp expected to post a loss of 12 cents a share - Earnings Preview
Vericel Corp reports results for the quarter ended in December - Earnings Summary
Brief: Vericel Reports Fourth Quarter And Full-Year 2021 Financial Results
Vericel Corp expected to post earnings of 14 cents a share - Earnings Preview
Brief: Vericel Announces Plans For A New State-Of-The-Art Cell Therapy Manufacturing Facility To Support Long-Term Growth
Brief: Vericel Corp - Estimates Its Full-Year Revenue Growth For Fiscal Year 2021 To Be In The Range Of 25%-26%
Vericel Corp reports results for the quarter ended in September - Earnings Summary
Brief: Vericel Reports Q3 Loss Per Share Of $0.11
Brief: Vericel Corp Entered Into A Sales Agreement With Svb Leerink Llc
Vericel Corp reports results for the quarter ended in June - Earnings Summary
Brief: Vericel Reports Second Quarter 2021 Results And Raises Full-Year 2021 Revenue Guidance
Vericel Corp expected to post a loss of 8 cents a share - Earnings Preview
MediWound down on FDA action, but Wall St sees eventual approval of burn treatment
U.S. RESEARCH ROUNDUP-Ceridian HCM Holding, Norwegian Cruise Line Holdings, Royal Caribbean Group
MediWound, Vericel tumble as FDA declines to approve burns treatment
NASDAQ RESUMED AT 09:35 AM
Brief: Vericel Corp Says Development Partner Mediwound Received CRL From U.S. FDA
NASDAQ TRADE HALT HALT NEWS PENDING AT 08:40 AM